PTO/SB/05 (11-00) Approved for use through 10/31/2002. OMB 0651-0032

Please type a plus sign (+) inside this box — U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

A068 US Attorney Docket No. Rennert First Inventor Antagonists of Tweak and of Tweak Receptor.

EL 475127482US

	nai applications under 37 CFR 1.53(t	Express Mail Label No. BETTELL TOLES	
APPLICA	ATION ELEMENTS	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application	
See MPEP chapter 600 con	cerning utility patent application conte	nts. Washington, DC 20231	
1. Submit an original and a	form (e.g., PTO/SB/17) duplicate for fee processing)	CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)	
2. See 37 CFR 1.27		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)	
3. Specification (preferred arrangement)	•	a. Computer Readable Form (CRF)	
	ce to Related Applications arding Fed sponsored R & D	b. Specification Sequence Listing on:i. X CD-ROM or CD-R (2 copies); or	
- Reference to se	equence listing, a table,		
- Background of		i i. [X] paper c. X Statements verifying identity of above copies	
	of the Invention on of the Drawings (if filed)	ACCOMPANYING APPLICATION PARTS	
- Detailed Descri		Assignment Papers (cover sheet & document(s))	
- Claim(s) - Abstract of the	Disclosure	10. 37 CFR 3.73(b) Statement Power of Attorney	
4. X Drawing(s) (35 U	J.S.C. 113) [Total Sheets 5	11. English Translation Document (if applicable)	
5. Oath or Declaration	[Total Pages 2]] Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations	
a. X Newly exec	uted (original or copy)	13. Preliminary Amendment	
b. Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
	ION OF INVENTOR(S) atement attached deleting inventor(s)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)	
named in	the prior application, see 37 CFR and 1.33(b).	16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35	
6. Application Data Sheet. See 37 CFR 1.76 or its equivalent. 17. Other:			
18. If a CONTINUING APPLI	CATION, check appropriate box, and	supply the requisite information below and in a preliminary amendment,	
or in an Application Data She		O(D)	
Prior application information:			
For CONTINUATION OR DIVIS	ExaminerIONAL APPS only: The entire disclosure	Group Art Unit:	
Box 5b, is considered a part o	f the disclosure of the accompanying co	entinuation or divisional application and is hereby incorporated by reference. advertently omitted from the submitted application parts.	
		ONDENCE ADDRESS	
Customer Number or Bar Co	ode Label (Insert Customer No. or Attach	or X Correspondence address below	
Name	Timothy P. Linkkila		
	BIOGEN, INC.		
Address	14 Cambridge Center		
City	Cambridge	State MA Zip Code 02142	
Country	USA	Telephone (617) 679-3795 Fax (617) 679-2833	
Name (Print/Type)	Timothy P. Linkkila	Registration No. (Attorney/Agent) 40,702	
Signature	Throthy P.	Tikle Date 7/13/01	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (09-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to re

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL		-	^-		/
TOTAL	MINIO	JINI	Ur.	PAI	MICH

(\$)	746
(Ψ)	740

espond to a collection of information	<u>unless it displays a valid OMB control numb</u> er		
Complete	e if Known		
Application Number			
Filing Date	July 13, 2001		
First Named Inventor	Rennert, Paul		
Examiner Name			
Group Art Unit			
Attorney Docket No.	A068 US		

	METHOD OF PAYMENT	FEE CALCULATION (continued)				
	1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES				
	Deposit	Large Entity Small Entity Fee Fee Fee Fee Fee Fee Description Fee Paid				
	Number U2-2321	Code (\$) Code (\$) ree Paid 105 130 205 65 Surcharge - late filing fee or oath				
	Deposit Account Name BIOGEN, INC.	127 50 227 25 Surcharge - late provisional filing fee or cover sheet				
	Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	139 130 139 130 Non-English specification				
	Applicant claims small entity status.	147 2,520 147 2,520 For filing a request for ex parte reexamination				
	See 37 CFR 1.27 2. Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action				
2 mi	Check Credit card Money Order Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action				
ü	FEE CALCULATION	115 110 215 55 Extension for reply within first month				
Ca Ca	1. BASIC FILING FEE	116 390 216 195 Extension for reply within second month				
۱D	Large Entity Small Entity	117 890 217 445 Extension for reply within third month				
O	Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	118 1,390 218 695 Extension for reply within fourth month				
ļΠ	101 710 201 355 Utility filing fee 710	128 1,890 228 945 Extension for reply within fifth month				
ţġ	106 320 206 160 Design filing fee	119 310 219 155 Notice of Appeal				
ļå	107 490 207 245 Plant filing fee	120 310 220 155 Filing a brief in support of an appeal				
1 11	108 710 208 355 Reissue filing fee	121 270 221 135 Request for oral hearing				
≆.	114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding				
-	SUBTOTAL (1) (\$) 710	140 110 240 55 Petition to revive - unavoidable				
7.4		141 1,240 241 620 Petition to revive - unintentional				
### ###	2. EXTRA CLAIM FEES Fee from	142 1,240 242 620 Utility issue fee (or reissue)				
	Extra Claims below Fee Paid	143 440 243 220 Design issue fee				
ii	Independent 3 3** = 0 × 0	144 600 244 300 Plant issue fee 122 130 122 130 Petitions to the Commissioner				
T.	Claims					
ļ.		The second second and second s				
	Large Entity Small Entity	126 240 126 240 Submission of Information Disclosure Stmt				
	Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)				
į	103 18 203 9 Claims in excess of 20	146 710 246 355 Filing a submission after final rejection (37 CFR § 1.129(a))				
	102 80 202 40 Independent claims in excess of 3 104 270 204 135 Multiple dependent claim, if not paid	149 710 249 355 For each additional invention to be examined (37 CFR § 1.129(b))				
	109 80 209 40 ** Reissue independent claims over original patent	179 710 279 355 Request for Continued Examination (RCE)				
	110 18 210 9 ** Reissue claims in excess of 20 and over original patent	169 900 169 900 Request for expedited examination of a design application				
	SUBTOTAL (2) (\$) 36	Other fee (specify)				
	**or number previously paid, if greater, For Reissues, see above	Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0				

SUBMITTED BY				Complete (if applicable)	
Name (Print/Type)	Timothy P. Linkkila	Registration No.	40,702	Telephone	(617) 679-3795
Signature	Timothy ?	Fildah		Date	7/13/01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

BIOGEN, INC.

Serial No.:

Not assigned yet

Filing Date:

Herewith

For:

Antagonists of Tweak and of Tweak Receptor and Their Use to

Treat Immunological Disorders

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office via Express Mail Label EL475127482US addressed to BOX PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date:

13 Auly 2007

Signature: __

Patricia Hofstetter

STATEMENT REGARDING SEQUENCE LISTING

Applicant hereby submits a diskette containing a machine-readable copy of the Sequence Listing done in FastSEQ 4.0.

The contents of the paper and computer readable copies are the same and, include no new matter, as required by 37 C.F.R. 1.821 (e). The sequences on the diskette and on the paper listing are identical to the sequences submitted in the application as filed.

Please charge our deposit account 02-2327 for any deficiencies.

Respectfully submitted,

Date: 7/13/01

Timothy P. Linkkira Reg. No. 40,702 BIOGEN, INC.

14 Cambridge Center Cambridge, MA 02142

(617) 679-3795